Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gaetano Morelli
Observed names:
G Morelli,
G. A. Morelli,
GAETANO MORELLI,
Gaetano Morelli, MD, FRCP
Institution:
Altasciences (Canada)
Observed institutions:
University of California, Los Angeles,
University of South Florida,
James A. Haley Veterans' Hospital,
World Health Organization,
Altasciences (Canada),
Allergan (United States),
Celerion (Canada),
Concordia University
show all 8
ORCID:
0009-0005-8238-8751
Observed ORCID:
0009-0005-8238-8751
OpenAlex ID:
A5103527855
Make science evolve into a One Health approach to improve health and security: a white paper
2020
·
Albert D. M. E. Osterhaus
, Chris Vanlangendonck
, et al.
·
One Health Outlook
·
90
PDF
Pharmacokinetics, Tolerability, and Performance of a Novel Matrix Transdermal Delivery System of Fentanyl Relative to the Commercially Available Reservoir Formulation in Healthy Subjects
2006
·
Jean‐Francois Marier
, Mary Lor
, et al.
·
The Journal of Clinical Pharmacology
·
51
Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation
2006
·
Jean‐Francois Marier
, Mary Lor
, et al.
·
British Journal of Clinical Pharmacology
·
26
PDF
Efficacy of NovoSeven® during surgery on a haemophiliac with previous history of inhibitors
2003
·
H. I. Saba
, G. A. Morelli
, et al.
·
Haemophilia
·
17
PDF
Pharmacokinetic Studies in Women of 2 Novel Oral Formulations of Tranexamic Acid Therapy for Heavy Menstrual Bleeding
2011
·
Keith A. Moore
, Isabelle Morin
, et al.
·
American Journal of Therapeutics
·
16
Steady-state pharmacokinetics of extended-release hydromorphone (OROS® hydromorphone): A randomized study in healthy volunteers
2011
·
Kenneth Todd Moore, MSc
, Dominique St-Fleur, BSc
, et al.
·
Journal of Opioid Management
·
15
A Randomized Study of the Effects of Food on the Pharmacokinetics of Once-Daily Extended-Release Hydromorphone in Healthy Volunteers
2010
·
Kenneth Todd Moore
, Dominique St-Fleur
, et al.
·
The Journal of Clinical Pharmacology
·
15
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
2024
·
Mette Søndergaard Nielsen
, Lise Brøndsted
, et al.
·
Diabetes Therapy
·
12
PDF
Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediateand extended-release formulations in healthy subjects
2006
·
Jean-Francois Marier
, Murray P. Ducharme
, et al.
·
Clinical Therapeutics
·
10
Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist
2009
·
Andrew E. Denker
, Gaetano Morelli
, et al.
·
Advances in Therapy
·
9
Integrated gastric acidity can predict the prevention of naproxen-induced gastroduodenal pathology in normal subjects
2003
·
John Plachetka
, Gaetano Morelli
, et al.
·
Gastroenterology
·
9
PDF
RLS-0071, a dual-targeting anti-inflammatory peptide - biomarker findings from a first in human clinical trial
2023
·
Jessica Goss
, Pamela Hair
, et al.
·
Translational Medicine Communications
·
6
PDF
Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants
2025
·
Xiao‐Jian Zhou
, Gaetano Morelli
, et al.
·
Clinical Pharmacology in Drug Development
·
5
PDF
Innovative strategies for early clinical R&D.
2008
·
Robert F Butz
, Gaetano Morelli
·
PubMed
·
5
Effects of zuranolone on next-day simulated driving in healthy adults
2024
·
Joi Dunbar
, Gaetano Morelli
, et al.
·
Psychopharmacology
·
3
PDF
859-P: ALN-KHK, an Investigational RNA Interference Therapeutic, Successfully Targets Hepatic Ketohexokinase in a Single Ascending Dose Study of Overweight to Obese Adults
2024
·
ELEFTHERIA MARATOS-FLIER
, TIRTHA NANDI
, et al.
·
Diabetes
·
2
W1086 Comparison of 24-Hour Intragastric pH Following Once-Daily Treatment With Esomeprazole and Six Rabeprazole Extended-Release Formulations
2010
·
Gaetano Morelli
, Huachun Chen
, et al.
·
Gastroenterology
·
2
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes
2026
·
Xiao‐Jian Zhou
, Alex Vo
, et al.
·
The Journal of Clinical Pharmacology
·
1
Pali-2108, a Colon Targeted Pde4b Inhibitor, Rapidly Restores Immune-epithelial Balance in Ulcerative Colitis Throughgut-selective Lymphocyte Depletion
2026
·
Joerg Heyer
, Patrick Collins
, et al.
·
Gastroenterology
·
1
P0989 Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1a Study
2026
·
J Heyer
, G Morelli
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters
2025
·
Xiao‐Jian Zhou
, Alex Vo
, et al.
·
The Journal of Clinical Pharmacology
·
1
PDF
WED-280 Pharmacokinetics of bemnifosbuvir in participants with renal impairment
2025
·
Xiao-Jian Zhou
, Gaetano Morelli
, et al.
·
Journal of Hepatology
·
1
Tu1438 GUT-TARGETED PDE4 INHIBITION WITH PALI-2108 DEMONSTRATES RAPID CLINICAL, HISTOLOGIC AND BIOMARKER IMPROVEMENT IN ULCERATIVE COLITIS: TRANSLATIONAL FINDINGS FROM A PHASE 1 STUDY
2026
·
Joerg Heyer
, Gaetano Morelli
, et al.
·
Gastroenterology
Tu1438 GUT-TARGETED PDE4 INHIBITION WITH PALI-2108 DEMONSTRATES RAPID CLINICAL, HISTOLOGIC AND BIOMARKER IMPROVEMENT IN ULCERATIVE COLITIS: TRANSLATIONAL FINDINGS FROM A PHASE 1 STUDY
2026
·
Joerg Heyer
, Gaetano Morelli
, et al.
·
Gastrointestinal Endoscopy
FRI-636 Bemnifosbuvir and ruzasvir administered as a fixed-dose-combination have lowpotential to inhibit P-gp, BCRP or OATP1B1/3 mediated transport
2026
·
Xiao-Jian Zhou
, Gaetano Morelli
, et al.
·
Journal of Hepatology
Show more works
View as search
Works count:
32
Citation count:
298
H-index:
9
I10-index:
9
Year
Topic
Type
